Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000411193 | SCV000487419 | likely pathogenic | Usher syndrome type 2A | 2016-08-18 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000412623 | SCV000490147 | likely pathogenic | Retinitis pigmentosa 39 | 2016-08-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000820967 | SCV000961706 | pathogenic | not provided | 2024-01-24 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Pro3116Hisfs*13) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (rs536593247, gnomAD 0.05%). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 24944099). ClinVar contains an entry for this variant (Variation ID: 371686). For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001074252 | SCV001239825 | pathogenic | Retinal dystrophy | 2019-04-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000820967 | SCV001804285 | pathogenic | not provided | 2023-03-28 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 34948090, 24944099, 27460420) |
Genome- |
RCV000412623 | SCV004182709 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000411193 | SCV004182710 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000412623 | SCV004207704 | pathogenic | Retinitis pigmentosa 39 | 2024-03-29 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000820967 | SCV004238394 | pathogenic | not provided | 2023-02-02 | criteria provided, single submitter | clinical testing | |
Laboratory of Human Genetics, |
RCV004699123 | SCV005201040 | pathogenic | Usher syndrome | 2024-05-01 | criteria provided, single submitter | research | The USH2A:c.9345del is a null variant in a gene where loss of function is a known mechanism of disease (PVS1), Extremely low frequency in gnomAD population databases (PM2), For recessive disorders, detected in trans with a pathogenic variant, or in a homozygous or compound heterozygous state in affected cases (PM3), Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease (PP1) , reported in ClinVar in affected individuals (PP5); it was detected in homozygosis in two affected siblings with Usher syndrome born from consanguineous couple. |
Fulgent Genetics, |
RCV005018704 | SCV005645070 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-03-28 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000411193 | SCV001457073 | pathogenic | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |